AbCellera Biologics Inc vs State Street PDR S&P Retail ETF — how do they compare? AbCellera Biologics Inc trades at $9.26 (market cap $2.99B), while State Street PDR S&P Retail ETF trades at $89.65. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | XRT | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.76 | $92.35 |
52-Week Low | $2.78 | $77.28 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
No Aura AI signal available yet.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →